



PERIMETER

Imaging Like You've Never Seen Before

Weekly IR Round-Up

Recognizing Our Most Recent Commercial Surgeon


Thank you Dr. Kory Jones, M.D., FACS -- our most recent surgeon to advocate for a commercial placement of Perimeter S-Series in her OR in order to bring OCT to her patients. We are grateful for your dedication to championing the latest advancements in surgical imaging technology and delivering top quality care to your patients!



#ICYMI: New OCT White Paper

Data from a newly published [white paper](#) showed a **5.6% reoperation rate** following primary breast conserving surgery (BCS) in the period after OCT imaging was adopted at the site.

Snapshot Slides



For comprehensive results and additional information, please refer to the [full white paper](#).

Perimeter Medical Imaging AI intends the sharing of this research and associated data for an investor audience and not for use by healthcare professionals. The data collected have not undergone peer review nor evaluation by FDA and should not be used to guide clinical practice.

Perimeter Medical Imaging was involved in the study design, data collection, analysis & interpretation, and the writing of the paper. Additionally, Perimeter funded professional medical writing support.

Mark Your Calendars!

Bristol Capital will be hosting a group investor call/webinar with us on **Tuesday, June 25th at 2 PM ET**. During the webcast, Perimeter's management including Adrian Mendes, CEO, Andrew Berkeley, CIO and Sara Brien, CFO, will conduct a presentation covering key areas of our business. After these

prepared remarks, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

Follow Perimeter Medical on Social!

The best way to hear the latest news from Perimeter is to follow us on one of our social media channels:

- **X** (formerly Twitter): <https://twitter.com/PerimeterMed>
- **LinkedIn**: <https://www.linkedin.com/company/perimeter-medical-imaging/>

You can also sign up to get Perimeter [news release alerts](#) delivered directly to your email or check out the news feed on our [investor website](#).

Information about the S-Series OCT Device

Intended Use

The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image review manipulation software for identifying and annotating regions of interest.

Unapproved Uses

The S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established.

For full information on unapproved/off-label uses, visit: <https://perimetermed.com/disclosures> or contact medicalaffairs@perimetermed.com.

*You are receiving this email because you signed up for news alerts from Perimeter Medical Imaging AI. Please use the "**Unsubscribe Preferences**" link below if you wish to opt out of this e-newsletter.*



Perimeter Medical Imaging AI, 8585 N. Stemmons Freeway, Suite 106N, Dallas, TX 75247

[Unsubscribe Preferences](#)

[TSXV: PINK](#) | [OTC PYNKF](#) | [FSE: 4PC](#)



© 2024 Perimeter Medical Imaging AI, Inc.